A5037941929- Pregnancy and Medication Impact
- Pharmacological Effects and Toxicity Studies
- Pregnancy and preeclampsia studies
- Maternal and fetal healthcare
- Gestational Diabetes Research and Management
- Reproductive Health and Contraception
- Chemical Safety and Risk Management
- Healthcare Regulation
- Drug Transport and Resistance Mechanisms
- Prenatal Substance Exposure Effects
- Maternal Mental Health During Pregnancy and Postpartum
- Maternal and Perinatal Health Interventions
- Intensive Care Unit Cognitive Disorders
- Pharmacogenetics and Drug Metabolism
- Dental Anxiety and Anesthesia Techniques
- Health Education and Validation
- Anesthesia and Pain Management
- Complementary and Alternative Medicine Studies
- Neonatal Health and Biochemistry
- Gender Roles and Identity Studies
- Epilepsy research and treatment
- Injury Epidemiology and Prevention
- Bee Products Chemical Analysis
- Emotional Intelligence and Performance
- Cardiovascular Issues in Pregnancy
Universidade de São Paulo
2013-2024
Universidade de Ribeirão Preto
2014
OBJETIVO: Comparar as características clínicas e laboratoriais, os resultados maternos perinatais de gestantes com pré-eclâmpsia versushipertensão gestacional. MÉTODOS: Análise retrospectiva dos prontuários médicos pacientes diagnóstico hipertensão gestacional, cujas gestações foram resolvidas em um período cinco anos. Foram coletadas informações obstétricos perinatais. As comparações entre grupos realizadas o uso do teste adequado para a variável analisada: testet não pareado, U...
Aims Diabetes mellitus can inhibit cytochrome P450 3A4, an enzyme responsible for the metabolism of nifedipine, used treatment hypertension in pregnant women. We aimed to assess effect type 2 diabetes (T2DM) on pharmacokinetics, placental transfer and distribution nifedipine amniotic fluid hypertensive Methods The study was conducted 12 women [control group (CG)] 10 with T2DM taking slow‐release (20 mg, 12/12 h). On 34th week gestation, serial blood samples were collected (0–12 h) after...
Considering that fluoxetine ( FLX ) is used to treat depressive states during pregnancy and it a cytochrome P450 CYP )2D6 inhibitor, which involved in the metabolism of both its enantiomers, this study aims describe enantioselective distribution metabolite norfluoxetine (Nor following single oral dose. Nine healthy pregnant women received 20 mg at 32 weeks gestation later day delivery. The apparent clearance (S)‐(+)‐ (1.45 vs. 0.66 L/hour/kg) area under plasma concentration time curve AUC...
This study aimed to develop and test common scenes of real life emotions in women. The methodology adopted herein combined qualitative quantitative methods involved three distinct stages: (i) use a descriptive question identify daily situations that evoked negative among women; (ii) construction everyday scenes; (iii) assessment how effectively the constructed videos manipulated emotions. visual analog scale (VAS), question, focus group were used discuss emotion neutral emotional condition...
Clinical experience shows an increased duration of labor in obese parturient women. It is unclear if this population should receive the same dose vaginal misoprostol for induction as non-obese We investigate influence obesity on pharmacokinetics and placental transfer metabolite acid Parturient women (n = 40) were enrolled received 25 µg/6 h vaginally allocated into two groups according to pre-pregnancy body mass index (BMI <30 kg/m
Background/Objectives: Fluoxetine (FLX) is the inhibitor of serotonin reuptake most prescribed in pregnant women with depression. This study evaluates influence gestational diabetes mellitus (GDM) on enantioselective pharmacokinetics and transplacental distribution FLX its metabolite norfluoxetine (norFLX). Methods: Ten diagnosed GDM (GDM group) were investigated third trimester gestation after they achieved good glycemic control. They received a single oral dose 20 mg FLX, blood samples...